WO2008009852A3 - Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009852A3
WO2008009852A3 PCT/FR2007/051678 FR2007051678W WO2008009852A3 WO 2008009852 A3 WO2008009852 A3 WO 2008009852A3 FR 2007051678 W FR2007051678 W FR 2007051678W WO 2008009852 A3 WO2008009852 A3 WO 2008009852A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
hyperseborrhoea
modulators
lanosterol synthetase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051678
Other languages
English (en)
Other versions
WO2008009852A2 (fr
Inventor
Fernand Labrie
Mohamed El-Alfy
Van Luu-The
Ezequiel L Calvo
Jerome Aubert
Pascal Collette
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to EP07823597A priority Critical patent/EP2046980A2/fr
Priority to CA002656908A priority patent/CA2656908A1/fr
Publication of WO2008009852A2 publication Critical patent/WO2008009852A2/fr
Anticipated expiration legal-status Critical
Priority to US12/320,171 priority patent/US20100021893A1/en
Publication of WO2008009852A3 publication Critical patent/WO2008009852A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de la lanostérol synthétase (LSS), ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
PCT/FR2007/051678 2006-07-19 2007-07-18 Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée Ceased WO2008009852A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07823597A EP2046980A2 (fr) 2006-07-19 2007-07-18 Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
CA002656908A CA2656908A1 (fr) 2006-07-19 2007-07-18 Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
US12/320,171 US20100021893A1 (en) 2006-07-19 2009-01-21 Modulators of lanosterol synthetase for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653026A FR2904002A1 (fr) 2006-07-19 2006-07-19 Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
FR0653026 2006-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,171 Continuation US20100021893A1 (en) 2006-07-19 2009-01-21 Modulators of lanosterol synthetase for treating acne or hyperseborrhea

Publications (2)

Publication Number Publication Date
WO2008009852A2 WO2008009852A2 (fr) 2008-01-24
WO2008009852A3 true WO2008009852A3 (fr) 2009-03-19

Family

ID=37684869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051678 Ceased WO2008009852A2 (fr) 2006-07-19 2007-07-18 Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20100021893A1 (fr)
EP (1) EP2046980A2 (fr)
CA (1) CA2656908A1 (fr)
FR (1) FR2904002A1 (fr)
WO (1) WO2008009852A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938343A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de cyp2b15 et/ou gpd1 pour le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048701A1 (fr) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines ou 4,1-benzothiazepines et leur utilisation comme inhibiteurs de squalene synthetase
WO2001056556A2 (fr) * 2000-02-02 2001-08-09 Warner-Lambert Company Doubles inhibiteurs de la synthese d'ester de choslesteryle et d'ester de cire utilises dans le traitement des troubles des glandes sebacees
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
US20020137131A1 (en) * 2001-03-23 2002-09-26 Ming-Hui Wei Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2004016608A1 (fr) * 2002-08-14 2004-02-26 Neurosearch A/S Nouveaux derives quinuclidiniques et leur utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
WO1997048701A1 (fr) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines ou 4,1-benzothiazepines et leur utilisation comme inhibiteurs de squalene synthetase
WO2001056556A2 (fr) * 2000-02-02 2001-08-09 Warner-Lambert Company Doubles inhibiteurs de la synthese d'ester de choslesteryle et d'ester de cire utilises dans le traitement des troubles des glandes sebacees
US20020137131A1 (en) * 2001-03-23 2002-09-26 Ming-Hui Wei Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2004016608A1 (fr) * 2002-08-14 2004-02-26 Neurosearch A/S Nouveaux derives quinuclidiniques et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BROWN G.R. ET AL.: "Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase : Optimization from lipids profiles.", J. MED. CHEM., vol. 42, no. 7, 1999, pages 1306 - 1311, XP002227318, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
FR2904002A1 (fr) 2008-01-25
CA2656908A1 (fr) 2008-01-24
EP2046980A2 (fr) 2009-04-15
US20100021893A1 (en) 2010-01-28
WO2008009852A2 (fr) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
WO2009100105A3 (fr) Inhibiteurs d'isoformes oncogènes et leurs utilisations
WO2012040499A3 (fr) Inhibiteurs métaboliques
WO2009124330A3 (fr) Traitement de maladies tumorales
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2005074985A3 (fr) Methodes de modulation de cd200
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008118390A3 (fr) Biomarqueurs pour procédés diagnostiques et thérapeutiques
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
GB2473575A (en) Treatment and diagnosis of behavioural disorders
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007038264A3 (fr) Methodes associees a gapr-1
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2007083287A3 (fr) Procédé d'essai permettant d'évaluer l'irritation de la peau
WO2007140308A3 (fr) Méthodes de criblage de modulateurs trpm4 de la sécrétion d'insuline
WO2009004247A3 (fr) Inhibiteurs de tace dans le traitement de l'acne
WO2006009950A3 (fr) Genes aldo utilises comme modificateurs de la voie igf et procedes d'utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007823597

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2656908

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU